Alpha Cognition Inc. (NASDAQ: ACOG) reported second-quarter 2026 results that underscore the strengthening launch of its Alzheimer's treatment ZUNVEYL, with net product revenue increasing 71% quarter-over-quarter to $6.0 million. This growth was driven by a 37% increase in bottles dispensed, reaching 8,294, and June emerged as the strongest month since launch with 2,997 bottles. Notably, this performance occurred without any material stocking benefit and with downstream pharmacy benefit manager (PBM) implementation remaining unchanged at approximately 16%, indicating that the quarter's results were fueled by genuine underlying demand and improved commercial execution.
The quarter revealed broadening adoption and deepening repeat utilization. Over 1,347 prescribers wrote ZUNVEYL prescriptions during the quarter, including 1,024 repeat prescribers, and the cumulative number of writers reached 1,908. Additionally, 1,095 long-term care (LTC) facilities generated prescriptions, highlighting the drug's penetration across both community and institutional settings. This expansion is particularly significant given that PBM implementation is still in its early stages, suggesting that as payer access broadens, the growth trajectory could accelerate further.
Alpha Cognition is strategically balancing commercial investment with a growing evidence base. The company lowered its full-year 2026 research and development (R&D) and selling, general, and administrative (SG&A) guidance to $50 million to $54 million, while maintaining its target of achieving operating profitability by 2027. Several key milestones are anticipated in the near term, including the CONVERGE data expected in the third quarter of 2026, the ongoing RESOLVE trial, and the sublingual program, which is gated by comparative pharmacokinetic results. These developments aim to enhance the product's value proposition and support the company's path toward greater operating leverage.
From a strategic perspective, the current setup for ZUNVEYL is characterized by breadth, depth, and payer upside. There remains significant white space among both prescribers and healthcare facilities, while the depth of utilization is increasing as patients and physicians gain experience with the therapy. The potential activation of broader PBM coverage represents an additional incremental growth driver that could materialize in the coming quarters.
Stonegate Capital Partners, which provides investor relations and equity research services, highlighted these positive trends in its updated coverage. The firm noted that the quality of the quarter was better than the access backdrop suggests, with prescriptions, repeat use, and facility adoption all advancing without broader formulary activation. Management indicated that growth continued into the third quarter, further reinforcing the positive momentum.
As Alpha Cognition continues to execute on its commercial strategy and build its clinical evidence, the company appears well-positioned to capitalize on the growing demand for ZUNVEYL. The combination of strong underlying demand, expanding prescriber base, and potential future payer wins could drive sustained growth as the year progresses.
